期刊
INFLAMMATION AND REGENERATION
卷 38, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s41232-018-0064-y
关键词
Rheumatoid arthritis; Joint destruction; Synovitis; Articular cartilage; Regeneration
资金
- pharmaceutical company (Chugai Pharmaceutical Co. Ltd)
- pharmaceutical company (UCB Japan Co. Ltd)
- pharmaceutical company (AYUMI Pharmaceutical Co.)
- Daiichi Sankyo Co. Ltd.
- Bristol-Myers
- Astellas
- Eli Lily
- Daiichi-Sankyo
- Abbvie
- Pfizer
- Taisho-Toyama
- pharmaceutical company (Mitsubishi Tanabe Pharma Co.)
- Nagahama City, Shiga, Japan
Background: Rheumatoid arthritis is an autoimmune inflammatory disease, the specific feature of which is progressive joint destruction induced by synovitis. The universal consensus is that alleviation of the synovitis is essential to prevent joint destruction and achieve clinical remission. Main text: We have shown that not only achieving but also maintaining remission is crucial to prevent the progression of joint destruction. Although regeneration of the damaged joints is considered very rare, accumulating evidence shows that it actually occurs in routine clinical practice as a result of strong inhibition of synovitis using highly potent medications. Oral and intravenous medications affect the whole body, but to promote joint regeneration in a particular joint, two potent options are intra-articular steroid injection and synovectomy. Conclusion: In situations where strong inhibition of synovitis combined with self-regeneration cannot repair severe joint destruction, regenerative medicine may in the future play a crucial role in the regeneration of damaged joints.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据